Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 29, 2020 07:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors

BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that...
June 12, 2020 06:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting

57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients 12.1 months median OS in intention-to-treat MDS patients with 9.7 months median duration of follow-up 13.7 months median OS...
June 03, 2020 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)

Topline data expected by year-end 2020Applications for US and EU regulatory approval planned for 2021 BOSTON, June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a...
May 18, 2020 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference

BOSTON, May 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
May 15, 2020 07:30 ET | Source: Aprea Therapeutics

Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations

BOSTON, May 15, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
April 06, 2020 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics Launches New Corporate Website - www.aprea.com

BOSTON, April 06, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate...
March 26, 2020 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
February 13, 2020 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial

BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that...
January 30, 2020 07:30 ET | Source: Aprea Therapeutics

Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation

BOSTON, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
January 09, 2020 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020

BOSTON, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right